Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Push who wrote (68)	7/14/1999 3:43:00 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 360

Another bionewbie question: Just how often during a disease process does a lab need to get tissue samples--say from cancer patients? Take RPR's Gencell /Introgen p53 gene therapy trial for instance (I assume you are still involved with that). My guess is that to build a useful gene expression database you would need samples of tumor at every stage of treatment--the molecular movie idea. It seems like this would be incredibly difficult, not only as far as all the lab work...but for the patients as well (sorry, a very unpleasant question, but are tumors continually, er, sampled?) Otherwise you would end up with a very choppy 'movie', just a few frames: Flash-- cancer inhibiting genes on, flash--they're off. Is my conceptualization too primitive to really get a hold on what you fellas do? I have this sci-fi image of what gene expression databases look like--moving 3D topographic maps, maybe it was your own website that implanted that in my noggin, can't seem to shake the image. __________ Thread: I'm happy to say I was able to take some trading profits in my wife's account today, and re-established for her a basic (non-trading) position in GLGC, it's not much, just that core 1000 shares, but it's a start. I don't really have any serious reservations about owning the stock--the Bancboston report suggests that GLGC will come close to breaking even next year, and that would certainly be a great accomplishment-- a trick many small biotechs haven't learned. The real problem is deciding where you want to put your money now that genomics oriented companies stocks are perking up--lately I've been thinking about Curagen and Hyseq again, but the fact that Steve is here on this thread is a wonderful move by the company, and obviously has something to do with my "first third". We need to make the best use of his presence that we can--it is a rare exception to the general rule for companies to ignore individual investors. Maybe if Steve can really sell us on GLGC I'll move up to a full position over the next few months... Asking the right questions is the trick-- I'll toss out a few attempts, but some help here would be appreciated. Maybe Rick can expand on his still unanswered question?--Flesh out what you were getting at for those of us who are not PhD's.

To: Steve Push who wrote (68)	12/13/1999 4:52:00 PM
From: scaram(o)uche	Respond to of 360

>> Yes, Rick Harmon's question is still on my to-do list. << So fast! Here's some more help...... Monday December 13, 4:00 pm Eastern Time Company Press Release SOURCE: Incyte Pharmaceuticals, Inc. Incyte and Oxford Gene Technology Ltd Cross License Microarray and Gene Expression Patents PALO ALTO, Calif., and OXFORD, United Kingdom, Dec. 13 /PRNewswire/ -- Incyte Pharmaceuticals, Inc. (Nasdaq: INCY - news) and Oxford Gene Technology Ltd, announced today that they have entered into a cross licensing agreement covering each other's microarray and gene expression technology patent portfolios. Financial terms of the agreement were not disclosed. Under terms of the agreement, Incyte has licensed from Oxford Gene Technology patents for inventions made by Professor Edwin Southern of Oxford University. These pioneering patents date from 1988 and cover fundamental technologies for the microarray and gene expression fields. The ''Southern Patents'' will be licensed to Incyte co-exclusively for the creation of large databases of gene expression data, which are licensed to multiple parties, and non-exclusively for all other uses. Oxford Gene Technology will obtain non-exclusive licenses from Incyte under Incyte's microarray and gene expression patent portfolio, which includes patents and patent applications covering microarrays, methods of manufacture of microarrays, gene expression analysis, sample preparation, and for identifying disease-associated genes using hybridization assays, which include microarray-based analysis. ''This agreement provides Incyte co-exclusive rights to the Southern Patents for the creation of large gene expression databases for multiple licensing,'' said Lee Bendekgey, General Counsel and Interim CFO of Incyte. ''We believe this patent portfolio will become one of the broadest in the microarray field, and that this license will give Incyte valuable freedom to operate as its microarray and expression programs expand and evolve. We are also pleased to be granting OGT a license to Incyte's extensive microarray and gene expression technology patent portfolio.'' ''We are delighted that this license to Incyte will widen access to array technology, especially for large-scale commercial high-density microarray products and services,'' said Ed Southern, Chairman of OGT. ''In addition, this agreement gives OGT access to key intellectual property from Incyte covering a broad range of technologies associated with the production and use of microarrays.'' Oxford Gene Technology was established to exploit the microarray and related technology arising from research carried out by Professor Southern and his team at the University of Oxford. In addition to its licensing activities, OGT has recently established an operational arm under the leadership of Dr. Andy Millar to provide services to the pharmaceutical and other sectors in antisense discovery, probe optimization, resequencing and expression analysis, employing techniques developed by Dr. Southern and his team. For more information visit OGT's Web site at www.ogt.co.uk. Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases, genomic data management software, microarray-based gene expression services, related reagents and services. These products and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's Web site at www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Annual Report on Form 10-Q for the quarter ended September 30, 1999. Incyte disclaims any intent or obligation to update these forward-looking statements. SOURCE: Incyte Pharmaceuticals, Inc.